Evidence map›Paper›PMID 38426169›Full record

ArticleFrontiers in neurology2024

Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis.

Luis Solís-Tarazona, Lars Lau Raket, Javier Cabello-Murgui, Salma Reddam, Silvia Navarro-Quevedo, Sara Gil-Perotin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Luis Solís-Tarazona *Research Group in Immunotherapy and Biomodels for Autoimmunity, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Lars Lau Raket *Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Javier Cabello-MurguiResearch Group in Immunotherapy and Biomodels for Autoimmunity, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Salma ReddamResearch Group in Immunotherapy and Biomodels for Autoimmunity, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Silvia Navarro-QuevedoNeurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Sara Gil-PerotinResearch Group in Immunotherapy and Biomodels for Autoimmunity, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Instituto de Investigación Sanitaria La Fe · ESHospital Universitari i Politècnic La Fe · ESLund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The assessment of serum neurofilament light chain (sNFL) has emerged as a diagnostic and prognostic tool in monitoring multiple sclerosis (MS). However, the application of periodic measurement in daily practice remains unclear. Objective: To evaluate the predictive value of individual sNFL levels in determining disease activity in patients with relapsing MS (RMS). Methods: In this two-year prospective study, 129 RMS patients underwent quarterly sNFL assessments and annual MRI scans. The study analyzed the correlation between individual NFL levels and past, current, and future disease activity. Group-level Z-scores were employed as a comparative measure. Results: Among the 37 participants, a total of 61 episodes of disease activity were observed. sNFL levels proved valuable in distinct ways; they were confirmatory of previous and current clinical and/or radiological activity and demonstrated a high negative predictive value for future 90 days activity. Interestingly, Z-scores marginally outperformed sNFL levels in terms of predictive accuracy, indicating the potential for alternative approaches in disease activity assessment. In our cohort, sNFL cut-offs of 10.8 pg./mL (sensitivity 27%, specificity 90%) and 14.3 pg./mL (sensitivity 15%, specificity 95%) correctly identified 7 and 4 out of 26 cases of radiological activity within 90 days, respectively, with 14 and 15% false negatives. When using lower cut-off values, individuals with sNFL levels below 5 pg/mL (with a sensitivity of 92%, specificity of 25%, and negative predictive value of 94%) were less likely to experience radiological activity within the next 3 months. Conclusion: Individual sNFL levels may potentially confirm prior or current disease activity and predict short-term future radiological activity in RMS. These findings underscore its periodic measurement as a valuable tool in RMS management and decision-making, enhancing the precision of clinical evaluation in routine practice.

Indexed as

biomarkermultiple sclerosisrelapseRMSZ-score

Identifiers

PMID38426169
PMCPMC10903281
OpenAlexW4391820227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.